Order Apifiny™ Test Kits today!

Information for
Healthcare Professionals
The only cancer specific, non-PSA blood test that may aid
clinicians in the detection of prostate cancer
Apifiny™ Prostate Cancer
0
Lower
Risk
59
Higher
Risk
100
Risk Assessment
Copyright © 2008-2015, Armune BioScience, Inc.
The only cancer specific, non-PSA blood test that may aid
clinicians in the detection of prostate cancer
What is Apifiny?
• Apifiny is a cancer specific blood test that measures the body’s
immune system response to prostate cancer.
• Apifiny measures eight autoantibodies released by the immune
system in response to the presence of prostate cancer.1
• Apifiny autoantibodies were discovered by research conducted
at the University of Michigan under the direction of Arul
Chinnaiyan, MD, PhD.2
• Apifiny does NOT rely on PSA or a calculation based on various
forms of PSA.
When should I order Apifiny?
• Apifiny may be used in men who have an elevated PSA
(>2.5 ng/ml) and are considering a prostate biopsy.
Why should I order Apifiny?
• Apifiny measures cancer specific biological markers that may
provide you with additional insight to support a clinical decision.
• In most cases, you already have the patient’s age, PSA level,
DRE result, personal and family health history.
• Order Apifiny when additional, unique biological information
may help to make a more informed clinical decision.
Given the complexity of cancer risk assessment, obtaining additional
biological information may provide insight to better inform an
important clinical decision such as an initial or repeat biopsy.
1. Translational Oncology, 2015; 8, 106-111
2. New England Journal of Medicine 2015; 353:1224-1235
Apifiny™ Prostate Cancer
0
Lower
Risk
59
Higher
Risk
100
Risk Assessment
How do I interpret an Apifiny Score?
Apifiny, combined with existing patient information and your clinical
experience, may aid in the assessment of prostate cancer risk.
Interpretation of Results for Lower Risk Patients:
“In the most recent peer-reviewed published study on
Apifiny,1 approximately 9 out of 10 men like you, with a
score of less than 59, were cancer free.”
Interpretation of Results for Higher Risk Patients:
“In the most recent peer-reviewed published study on
Apifiny,1 approximately 1 out 3 men like you, with a score of
59 or above, had prostate cancer. You may be at higher risk.”
What will Apifiny cost my patients?
Medicare, Medicaid, and private insurance companies may
cover the cost of the Apifiny test. Current reimbursement and
other payment information can be found on the company’s
website at www.armune.com.
Order Apifiny™
Test Kits today!
Apifiny™ Prostate Cancer
0
Lower
Risk
59
Higher
Risk
100
Risk Assessment
The only cancer specific, non-PSA blood test that may aid
clinicians in the detection of prostate cancer
Armune BioScience, Inc.
401 West Morgan Road
Ann Arbor, MI 48108
Toll Free Helpline: 844-427-6863
www.armune.com
Apifiny is performed in the Armune BioScience high-complexity CLIA laboratory.
CT-029 Rev.03 06/08/15